Titan Spine recently announced a 51% increase in sales of its Endoskeleton interbody fusion devices in 2015 compared with sales for the previous year.
The company also reported more than $33.5 million in worldwide sales in 2015, with sales in the fourth quarter of 2015 equating to an annualized run rate of $43.1 million, according to information in a press release from Titan Spine. The company reported more than 400 hospital customers worldwide and exceeded 110 distributors in 2015. In addition, approximately 10,000 Endoskeleton implants were sold in 2015 and 44,000 have been sold since its inception, according to the release.
“Titan Spine exceeded growth expectations in 2015, which is a testament to the efforts of our expanding sales team and the growing adoption of titanium and our specific surface technology for interbody fusion devices. This past year has marked a significant inflection point for our company, and we look forward to continued success in 2016 as we further differentiate our product offerings with the release of our next-generation nanoLOCK surface technology, which represents the only FDA-cleared nanotechnology for the spine,” Steve Cichy, vice president of sales of Titan Spine, said in the release.
The full line of Endoskeleton devices features Titan Spine’s proprietary implant surface technology, which is a combination of roughed topographies at the macros, micro and nano levels.